Attorney's Docket No. 004101-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Patent Application of)
Maurice ISRAEL et al.	,)
Application No.: UNASSIGNED (Corresponds to PCT/FR00/01612)) Group Art Unit: UNASSIGNED)
International Filing Date: 9 JUNE 2000)) Examiner: UNASSIGNED
For: PHARMACEUTICAL COMPOSITION	,
COMPRISING NO OR AT LEAST A)
NO DONOR COMPOUND OR)
ANOTHER COMPOUND CAPABLE)
OF RELEASING OR INDUCING NO)
FORMATION IN CELLS)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Copies of the references have been forwarded to the U.S. Designated/Elected Office by WIPO.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

Information Disclosure Statement Application No. <u>Unassigned</u> Attorney's Docket No. <u>004101-003</u> Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialled copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:

Teresa Stanek Rea

Registration No. 30,427

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: DECEMBER 10, 2001

10/009198 SHEET 1 OF 3 SHEET 1 OF 3 DEC 2001

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKTING FREC'U	APPLICATION NOW DEC 20 UNASSIGNED
APPLICANT Maurice ISRAEL et al.	
INT'L FILING DATE	GROUP UNASSIGNED

			U.S. PATENT DOCUM	IENIS				
Examiner	U.S. Patent Do	cument Kind Code	Name of Patentee			Date of Publication (MM-DD-YYYY)		
Initials	Number E 995 621	(if known)	of Cited Doc H.C. Alvin et al.	ument	03/23/19			
	5,885,621		II.C. Alviii ct di.					
1		F	OREIGN PATENT DOC	UMENTS				
	Foreign Patent				Date of Publication	Trans	slation	
Examiner Initials	Number	Kind Code (if known)	Country		(MM-DD-YYYY)	Yes	nc	
initials	WO 97/33173		PCT		09/12/1997		 —	
	DE 29709820		GERMANY		07/31/1997		↓_	
	WO 96/02241		PCT		02/01/1996		∔—	
-	WO 99/01427		PCT		01/14/1999		↓_	
	WO 98/13358		PCT		04/02/1998		┼-	
	EP 0 870 763		EUROPE		10/14/1998		┼-	
	WO 97/25984		PCT		07/24/1997			
			PATENT LITERATURE			 _		
Examiner	item (book	magazine, jo	urnal, serial, symposium, ca nublisher, city and/or co	talog, etc.), da untry where pu	e (when appropriate), title o te, page(s), volume-issue nu iblished.			
Shuichi YAMADA: "Effects on ATP and amino acid mixtures on progressive muscular dystrophy," SAPPORO IC ZASSHI (1965), 27, 284-97 XP002131218 D.S. BREDT, "Endogenous nitric oxide synthesis: Biological functions and pathophysiology," FREE RADICAL RESEARCH (1999) 31/6, PP. 577-596, XP002131219 J.W. HAYCOCK et al., "Oxidative damage to muscle protein in Duchenne muscular dystrophy," NEUROREPOR Vol. 8, No. 1, pp, 357-361, XP000879014 D.S. CHAO et al.: "Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrohpy," J. Exp. (1996), 184(2), pp. 609-618 L. ROMAULD et al.: "Neuronal nitric oxide synthase isoforms.alpha.and.mu. are closely related calpain-sensity."							KU	
							(19	
	Droteins," MOL. PHARMACOL. (1998), 54(2), pp. 305-312 A. DECRORY et al.: "Mini- and full-length dystrophin gene transfer induces the recovery of nitric oxide synthase sarcolemma of mdx4cv skeletal muscle fibers," GENE THERAPY, (1998), 5(1), pp. 59-64 G.B. AZZENA et al.: "Nitric oxide regenerates the normal colonic peristaltic activity in mdx dystrophic mouse," NEUROSCIENCE LETTERS, (1999), 261, (1-2), pp. 9-12							
-								
				Date				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	SHEET 2056	.อกกร
ATTORNEY'S DKT NOW TO THE OUT OF THE OUT OF THE OUT OF THE OUT	UNASSIGNED	2001
APPLICANT Maurice ISRAEL et al.		
INT'L.FILING DATE 9 June 2000	GROUP UNASSIGNED	

			J.S. PATENT DOCUM	IENIS				
	U.S. Patent Document				Data of Bublic	Date of Publication		
Examiner Initials	Number	Kind Code (if known)	Name of Patentee of Cited Doc	or Applicant ument	(MM-DD-YY			
			REIGN PATENT DOC	UNIENIS		T	 -	
Examiner	Foreign Patent	Nocument Kind Code			Date of Publication		lation	
Initials	Number	(if known)	Country PCT		(MM-DD-YYYY) 10/26/1995	Yes	no	
	WO 95/28377		FCI		, 6, 20, 100			
	 							
			ATENT LITERATURE					
Examiner Initials	item (book,	, magazine, jour	nal, serial, symposium, ca publisher, city and/or co	talog, etc.), a untry where p	cle (when appropriate), title of ate, page(s), volume-issue nun published.			
initials	G.D. THOMAS et al.: "Impaired metabolic modulation of alpha-adrenergic," PROC. NAT'L. ACAD. SCIENCES USA,							
	CHAUBOURT et al.	: "Nitric oxide a	<i>f</i>		tutrophin at the" NEUROBIC			
	W.H. WAUGH et al	.: "Evidence th	at L-arginine is a key amin		le cell anemia", NUTR. RES	(N.Y.) (1999) ——	
	A N. SCHECHTER	"NO Therapy."	JOURNAL OF CLIN. INVE	STIGATION (1997), 100/5, PP. 955-956	(1997)		
	1400/EV DD 1100 1	1100			en affinity", J. CLIN. INVEST			
	S.P. PERRINE et al.: "Butyrate-induced reactivation of the fetal globin genes", EXPERIENTIA, BIRKHAUSER VERL BASEL, CH. Vol. 49, No. 2 (1993) PP. 133-137							
	D. DA CELLI et el e	"Lludrovuurea r	eacts with heme proteins	to generate ni	itric oxide," LANCET (1996), 3	5/1998)	5 (900 Vol.	
	IOO No 10 Cunni	1 Dart 1-2 nn	69h A		n in patients", BLOOD (11/1			
	C.O. ENWONWU: 997-998	"Increased met	abolic demand for arginine	in sickle cell	anemia," MED. SCI. RES. (19	39), 17(2	23), PI	
Examiner Signature				Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

10/009198

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NOTO FILE	APPEICATION NO.
004101-003	UNASSIGNED
APPLICANT	
Maurice ISRAEL et al.	
INT'L. FILING DATE	GROUP
9 June 2000	UNASSIGNED

			U.S. PATENT DOCUM	MENTS				
	U.S. Patent Document							
Examiner Initials	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document			Date of Publication (MM-DD-YYYY)		
						· · · · · · · · · · · · · · · · · · ·		
							-	
								
			REIGN PATENT DOC	UMENTS		T		
	Foreign Paten			İ	Date of Publication	Trans	lation	
Examiner Initials	Number	Kind Code (if known)	Country		(MM-DD-YYYY)	Yes	no	
		1				-	<u> </u>	
						-	<u> </u>	
			ATENT LITERATURE					
Examiner	Includ item (bod	le name of author k, magazine, jour	nal, serial, symposium, ca	talog, etc.), d	cle (when appropriate), title of late, page(s), volume-issue nur published.	the nber(s),		
Initials	publisher, city and/or country where published. G.D. SHER et al.: "Extended therapy with intravenous arginine butyrate in patients with beta", NEW ENG. J. OF MED., (1995) 332/24, PP. 1606-1610							
	C.R. MORRIS et a	I.: "L-arginine th	erapy paradoxically decrea VOL. 45, NO. 4, PART 2,	ises nitric oxid	de production in patients with	sickle ce	(I	
	A.M. ATZ et al.: VOL. 87, NO. 4,	"Inhaled nitric ox	ide in sickle cell disease w	ith acute che	est syndrome," ANESTHESIOLO	GY (199) 7),	
	VUL. 87, NU. 4,	11. 300-330						
	<u> </u>							
				Data				
Examiner Signature				Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.